FOXO4-DRI is a senescence-research peptide designed to disrupt the FOXO4-p53 interaction. Typical experiments assess selective apoptosis of senescent cells, p53/BCL-2/caspase signaling, senescence burden, and downstream tissue-homeostasis markers.

What this formula features: A targeted protein-protein-interaction strategy rather than a general cytotoxic agent. Preclinical research has shown that disrupting FOXO4-p53 can restore p53-driven apoptosis preferentially in senescent cells and alter markers of tissue homeostasis.

Typical research readouts: Researchers commonly measure senescent-cell viability, p53 localization/signaling, BCL-2 and caspase markers, apoptosis, senescence-associated secretory phenotype markers, and tissue-function readouts in aging models. Selectivity versus non-senescent controls is a critical endpoint.

This product is strictly for research purposes only. Not approved for human or animal use.